Exicure (XCUR) Competitors $5.09 -0.01 (-0.20%) Closing price 04:00 PM EasternExtended Trading$5.14 +0.05 (+0.96%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. ATRA, MGNX, COYA, BMEA, WHWK, HLVX, MEIP, CNTX, ADVM, and ALXOShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Atara Biotherapeutics (ATRA), MacroGenics (MGNX), Coya Therapeutics (COYA), Biomea Fusion (BMEA), Whitehawk Therapeutics (WHWK), HilleVax (HLVX), MEI Pharma (MEIP), Context Therapeutics (CNTX), Adverum Biotechnologies (ADVM), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors Atara Biotherapeutics MacroGenics Coya Therapeutics Biomea Fusion Whitehawk Therapeutics HilleVax MEI Pharma Context Therapeutics Adverum Biotechnologies ALX Oncology Atara Biotherapeutics (NASDAQ:ATRA) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Do analysts prefer ATRA or XCUR? Atara Biotherapeutics currently has a consensus price target of $21.00, indicating a potential upside of 37.43%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more volatility and risk, ATRA or XCUR? Atara Biotherapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.76, suggesting that its share price is 276% more volatile than the S&P 500. Does the media refer more to ATRA or XCUR? In the previous week, Atara Biotherapeutics had 2 more articles in the media than Exicure. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 1 mentions for Exicure. Exicure's average media sentiment score of 0.95 beat Atara Biotherapeutics' score of 0.73 indicating that Exicure is being referred to more favorably in the news media. Company Overall Sentiment Atara Biotherapeutics Positive Exicure Positive Is ATRA or XCUR more profitable? Atara Biotherapeutics has a net margin of 3.07% compared to Exicure's net margin of 0.00%. Atara Biotherapeutics' return on equity of -8.34% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets Atara Biotherapeutics3.07% -8.34% 6.61% Exicure N/A -192.16%-84.30% Do institutionals and insiders believe in ATRA or XCUR? 70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 4.0% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 52.8% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, ATRA or XCUR? Exicure has lower revenue, but higher earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtara Biotherapeutics$128.94M0.83-$85.40M-$0.43-35.53Exicure$500K64.34-$9.70M-$3.88-1.31 SummaryAtara Biotherapeutics beats Exicure on 11 of the 16 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.22M$3.38B$6.11B$10.47BDividend YieldN/A2.29%5.73%4.77%P/E RatioN/A8.3264.8323.34Price / Sales64.34488.16608.74136.45Price / CashN/A46.7037.4661.86Price / Book4.5410.5512.426.81Net Income-$9.70M-$52.58M$3.32B$276.80M7 Day Performance-4.32%1.09%1.01%0.27%1 Month Performance25.06%16.09%10.75%8.31%1 Year Performance126.22%18.41%76.20%35.60% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.7284 of 5 stars$5.09-0.2%N/A+97.7%$32.22M$500K0.0050ATRAAtara Biotherapeutics4.6017 of 5 stars$15.20+8.7%$21.00+38.2%+79.3%$107.41M$128.94M-35.58330Gap UpMGNXMacroGenics4.4364 of 5 stars$1.70-3.7%$3.60+112.4%-62.4%$107.14M$149.96M-2.97430Positive NewsCOYACoya Therapeutics2.4746 of 5 stars$6.32-2.8%$16.20+156.3%-8.2%$105.73M$3.55M-5.106BMEABiomea Fusion3.3299 of 5 stars$1.77-33.9%$9.50+438.2%-84.0%$105.63MN/A-0.5950High Trading VolumeWHWKWhitehawk Therapeutics1.0207 of 5 stars$2.23+3.7%N/AN/A$105.10M$25.98M-37.1721HLVXHilleVax1.1969 of 5 stars$2.09flat$2.00-4.3%N/A$104.79MN/A-1.4620MEIPMEI Pharma0.6485 of 5 stars$3.19+14.7%N/A+19.4%$104.72MN/A-0.67100Gap UpHigh Trading VolumeCNTXContext Therapeutics3.2332 of 5 stars$1.15-5.4%$5.20+354.1%-30.7%$102.71MN/A-3.187Gap UpADVMAdverum Biotechnologies3.7957 of 5 stars$4.85-8.5%$19.75+307.2%-40.6%$101.75M$1M-0.62190ALXOALX Oncology3.9673 of 5 stars$1.88-10.9%$3.30+75.5%+9.7%$100.94MN/A-0.8640 Related Companies and Tools Related Companies Atara Biotherapeutics Alternatives MacroGenics Alternatives Coya Therapeutics Alternatives Biomea Fusion Alternatives Whitehawk Therapeutics Alternatives HilleVax Alternatives MEI Pharma Alternatives Context Therapeutics Alternatives Adverum Biotechnologies Alternatives ALX Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
